Five studies were conducted using a mixed BC population and one was conducted using HER2-positive and TNBC patients, whereas the remaining investigations focused on a specific BC subtype (i.e., HER2-positive, HER2-negative, HR-positive, and Luminal B). This evidence concerns the gene ERBB2 and breast cancer.